Convection-Enhanced Delivery in the Treatment of Epilepsy

Neurotherapeutics

Volumn 6, Issue 2, 2009, Pages 344-351

  Rogawski, Michael A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

conotoxin; antiepileptic drug; botulinum neurotoxin; Convection enhanced delivery; drug delivery; epilepsy; kindling; seizure

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; CARBAMAZEPINE; IBOTENIC ACID; NEUROTRANSMITTER; OMEGA CONOTOXIN GVIA; OMEGA CONOTOXIN MVIIA;

AMYGDALOID NUCLEUS; ARTICLE; ATAXIA; BLOOD BRAIN BARRIER; BRAIN REGION; BYSTANDER EFFECT; CHRONIC PAIN; CONFUSION; CONTINUOUS INFUSION; CONVECTION ENHANCED DELIVERY; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INFUSION; EPILEPSY; EPILEPTIC DISCHARGE; EPILEPTIC FOCUS; FOCAL EPILEPSY; GAIT DISORDER; HUMAN; HYPOTENSION; LOCAL THERAPY; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICONVULSANTS; CONVECTION; DRUG DELIVERY SYSTEMS; EPILEPSY; HUMANS;

EID: 62949187356     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2009.01.017     Document Type: Article

References (61)

1. Nilsen K.E., and Cock H.R. Focal treatment for refractory epilepsy: hope for the future?. Brain Res Brain Res Rev 44 (2004) 141-153
2. Fisher R.S., and Chen D.K. New routes for delivery of anti-epileptic medications. Acta Neurol Taiwan 15 (2006) 225-231
3. Barcia J.A., and Gallego J.M. Intraventricular and intracerebral delivery of anti-epileptic drugs in the kindling model. Neurotherapeutics 6 (2009) 337-343
4. Anschel D.J., Ortega E.L., Kraus A.C., and Fisher R.S. Focally injected adenosine prevents seizures in the rat. Exp Neurol 190 (2004) 544-547
5. Fiandaca M.S., Forsayeth J.R., Dickinson P.J., and Bankiewicz K.S. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 5 (2008) 123-127
6. Ludvig N., Kuzniecky R.I., Baptiste S.L., et al. Epidural pentobarbital delivery can prevent locally induced neocortical seizures in rats: the prospect of transmeningeal pharmacotherapy for intractable focal epilepsy. Epilepsia 47 (2006) 1792-1802
7. John J.E., Baptiste S.L., Sheffield L.G., et al. Transmeningeal delivery of GABA to control neocortical seizures in rats. Epilepsy Res 75 (2007) 10-17
8. Ludvig N., Baptiste S.L., Tang H.M., et al. Localized transmeningeal muscimol prevents neocortical seizures in rats and nonhuman primates: therapeutic implications. Epilepsia (2008) Dec 2 [Epub ahead of print]
9. Kokaia M., Aebischer P., Elmér E., et al. Seizure suppression in kindling epilepsy by intracerebral implants of GABA- but not by noradrenaline-releasing polymer matrices. Exp Brain Res 100 (1994) 385-394
10. Kubek M., Liang D., Byrd K., and Domb A. Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation. Brain Res 809 (1998) 189-197
11. Tamargo R.J., Rossell L.A., Kossoff E.H., Tyler B.M., Ewend M.G., and Aryanpur J.J. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res 48 (2002) 145-155
12. López T., Ortiz E., Quintana P., and González R.D. A nanostructured titania bioceramic implantable device capable of drug delivery to the temporal lobe of the brain. Colloids Surf A: Physicochem Eng Asp 300 (2007) 3-10
13. McCown T.J. Adeno-associated virus-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity in vivo. Mol Ther 14 (2006) 63-68
14. Noè F., Pool A.H., Nissinen J., et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 131 pt 6 (2008) 1506-1515
15. Carpentino J.E., Hartman N.W., Grabel L.B., and Naegele J.R. Region-specific differentiation of embryonic stem cell-derived neural progenitor transplants into the adult mouse hippocampus following seizures. J Neurosci Res 86 (2008) 512-524
16. Noé F., Frasca1 A., Balducci C., et al. Neuropeptide Y overexpression using recombinant adenoassociated viral vectors. Neurotherapeutics 6 (2009) 300-306
17. McCown T.J. Adeno-associated virus vector-mediated expression and constitutive secretion of galanin suppresses limbic seizure activity. Neurotherapeutics 6 (2009) 307-311
18. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., and Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91 (1994) 2076-2080
19. Lieberman D.M., Laske D.W., Morrison P.F., Bankiewicz K.S., and Oldfield E.H. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82 (1995) 1021-1029
20. Haroun R.I., and Brem H. Local drug delivery. Curr Opin Oncol 12 (2000) 187-193
21. Lonser R.R., Walbridge S., Garmestani K., et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 97 (2002) 905-913
22. MacKay J.A., Deen D.F., and Szoka Jr. F.C. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 1035 (2005) 139-153
23. Morrison P.F., Laske D.W., Bobo H., Oldfield E.H., and Dedrick R.L. High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol 266 1 pt 2 (1994) R292-R305
24. Sampson J.H., Raghavan R., Brady M.L., et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 9 (2007) 343-353
25. Laske D.W., Youle R.J., and Oldfield E.H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3 (1997) 1362-1368
26. Rand R.W., Kreitman R.J., Patronas N., Varricchio F., Pastan I., and Puri R.K. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6 (2000) 2157-2165
27. Voges J., Reszka R., Gossmann A., et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 54 (2003) 479-487
28. Lidar Z., Mardor Y., Jonas T., et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100 (2004) 472-479
29. Sampson J.H., Akabani G., Archer G.E., et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 10 (2008) 320-329
30. Gill S.S., Patel N.K., Hotton G.R., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9 (2003) 589-595
31. Lang A.E., Gill S., Patel N.K., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59 (2006) 459-466
32. Patel N.K., and Gill S.S. GDNF delivery for Parkinson's disease. Acta Neurochir Suppl 97 pt 2 (2007) 135-154
33. Kaplitt M.G., Feigin A., Tang C., et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369 (2007) 2097-2105
34. Marks Jr. W.J., Ostrem J.L., Verhagen L., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7 (2008) 400-408
35. Kaplitt MG, During MJ, inventors. Infusion device and method for infusing material into the brain of a patient. US patent application 2006;0129126 A1 (application 11/280,965).
36. Krauze M.T., Saito R., Noble C., et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 103 (2005) 923-939
37. Neeves K.B., Lo C.T., Foley C.P., Saltzman W.M., and Olbricht W.L. Fabrication and characterization of microfluidic probes for convection enhanced drug delivery. J Control Release 111 (2006) 252-362
38. Ai Y., Markesbery W., Zhang Z., Grondin R., Elseberry D., Gerhardt G.A., and Gash D.M. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol 461 (2003) 250-261
39. Bennewitz M.F., and Saltzman W.M. Nanotechnology for the delivery of drugs to the brain for epilepsy. Neurotherapeutics 6 (2009) 323-336
40. Richardson R.M., Larson P.S., and Bankiewicz K.S. Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models. Neurosurgery 63 (2008) 629-644
41. Smith D.C., Krahl S.E., Browning R.A., and Barea E.J. Rapid cessation of focally induced generalized seizures in rats through microinfusion of lidocaine hydrochloride into the focus. Epilepsia 34 (1993) 43-53
42. Eder H.G., Stein A., and Fisher R.S. Interictal and ictal activity in the rat cobalt/pilocarpine model of epilepsy decreased by local perfusion of diazepam. Epilepsy Res 29 (1997) 17-24
43. Eder H.G., Jones D.B., and Fisher R.S. Local perfusion of diazepam attenuates interictal and ictal events in the bicuculline model of epilepsy in rats. Epilepsia 38 (1997) 516-521
44. Stein A.G., Eder H.G., Blum D.E., Drachev A., and Fisher R.S. An automated drug delivery system for focal epilepsy. Epilepsy Res 39 (2000) 103-114
45. Gasior M., White N.A., and Rogawski M.A. Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists ω-conotoxin GVIA and ω-conotoxin MVIIA. J Pharmacol Exp Ther 323 (2007) 458-468
46. Heiss J.D., Walbridge S., Morrison P., et al. Local distribution and toxicity of prolonged hippocampal infusion of muscimol. J Neurosurg 103 (2005) 1035-1045
47. Bowersox S.S., and Luther R. Pharmacotherapeutic potential of ω-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon 36 (1998) 1651-1658
48. Westenbroek R.E., Hell J.W., Warner C., Dubel S.J., Snutch T.P., and Catterall W.A. Biochemical properties and subcellular distribution of an N-type calcium channel α1 subunit. Neuron 9 (1992) 1099-1115
49. Boulton C.L., and O'Shaughnessy C.T. The effect of calcium channel antagonists on spontaneous and evoked epileptiform activity in the rat neocortex in vitro. Eur J Neurosci 3 (1991) 992-1000
50. 2+ channel toxins in DBA/2 mice. Psychopharmacology (Berl) 126 (1996) 85-90
51. 2+ channels blockers in generalized absence epilepsy. Eur J Pharmacol 406 (2000) 381-389
52. Wang S., Ding M., Wu D., Zhan J., and Chen Z. ω-Conotoxin MVIIA inhibits amygdaloid kindled seizures in Sprague-Dawley rats. Neurosci Lett 413 (2007) 163-167
53. Williams J.A., Day M., and Heavner J.E. Ziconotide: an update and review. Expert Opin Pharmacother 9 (2008) 1575-1583
54. Verderio C., Pozzi D., Pravettoni E., et al. SNAP-25 modulation of calcium dynamics underlies differences in GABAergic and glutamatergic responsiveness to depolarization. Neuron 41 (2004) 599-610
55. Matteoli M., Pozzi D., Grumelli C., et al. The synaptic split of SNAP-25: Different roles in glutamatergic and GABAergic neurons?. Neuroscience 158 (2009) 223-230
56. Verderio C., Grumelli C., Raiteri L., et al. Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 8 (2007) 142-153
57. Costantin L., Bozzi Y., Richichi C., et al. Antiepileptic effects of botulinum neurotoxin E. J Neurosci 25 (2005) 1943-1951
58. Bozzi Y., Costantin L., Antonucci F., and Caleo M. Action of botulinum neurotoxins in the central nervous system: antiepileptic effects. Neurotox Res 9 (2006) 197-203
59. Cohen-Gadol A.A., Wilhelmi B.G., Collignon F., et al. Long-term outcome of epilepsy surgery among 399 patients with nonlesional seizure foci including mesial temporal lobe sclerosis. J Neurosurg 104 (2006) 513-524
60. Pace J.R., Lonser R.R., Kirkby R.D., Jeffries N., Rogawski M.A., and Oldfield E.H. Epileptiform activity extinguished by amygdala infusion of the neurotoxin ibotenate in a rat model of temporal lobe epilepsy. J Neurosurg 97 (2002) 450-454
61. Wiley R.G., and Kline IV R.H. Neuronal lesioning with axonally transported toxins. J Neurosci Methods 103 (2000) 73-82